Approvals

FDA approves TRIKAFTA to treat the underlying cause of cystic fibrosis

Vertex Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation.

Alexion receives FDA approval for ULTOMIRIS for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved ULTOMIRIS (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) for adult and pediatric (one month of age and older) patients.

FDA approves AstraZeneca’s Farxiga to treat heart failure in diabetic patients

AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.

FDA approves Roche’s Xofluza for patients at high risk of developing flu-related complications

Roche has secured approval from the US Food and Drug Administration (FDA) for its Xofluza (baloxavir marboxil) to treat people at high risk of developing influenza-related complications.

Janssen, Bayer get FDA nod for Xarelto to prevent VTE in acutely ill medical patients

Bayer and Janssen Research & Development have secured approval from the US Food and Drug Administration (FDA) for Xarelto (rivaroxaban) to prevent blood clots in acutely ill medical patients.

Eli Lilly gets FDA approval for migraine drug Reyvow

Eli Lilly has secured approval from the US Food and Drug Administration (FDA) for its Reyvow (lasmiditan) for the acute treatment of migraine.

Novartis’ Beovu secures FDA approval for wet AMD treatment

Novartis' Beovu (brolucizumab) injection has secured approval from the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD).

Pfenex’ Forteo biosimilar PF708 secures FDA approval for osteoporosis

Pfenex has secured approval for PF708, a biosimilar of Forteo (teriparatide injection), from the US Food and Drug Administration (FDA) for the treatment of osteoporosis in certain patients who are highly prone to fracture.

Fasenra approved in the US for self-administration in a new pre-filled auto-injector, the Fasenra Pen

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen).